The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Abstract
Adriamycin (doxorubicin), a potent antitumor drug in clinical use, interacts with nucleic acids and cell membranes, but the molecular basis for its antitumor activity is unknown. Similar to a number of intercalative antitumor drugs and nonintercalative epipodophyllotoxins (VP-16 and VM-26), adriamycin has been shown to induce single- and double-strand breaks in DNA. These strand breaks are unusual because a covalently bound protein appears to be associated with each broken phosphodiester bond. In studies in vitro, mammalian DNA topoisomerase II mediates DNA damage by adriamycin and other related antitumor drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fridovich (1978) · doi:10.1126/science.210504 · Cited by 3,329
Gellert, M. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.004311 · Cited by 989
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
Self-citationThe Anticancer Agent Adriamycin Can Be Actively Cytotoxic Without Entering Cells
Triton, T. R., & Yee, G. (1982) · Science · doi:10.1126/science.7089561 · Cited by 571
Nelson, E. M., Tewey, K. M., & Liu, L. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1361 · Cited by 558
Self-citationLIU, L., LIU, C., & ALBERTS, B. (1980) · Cell · doi:10.1016/s0092-8674(80)80046-8 · Cited by 550
Self-citationCleavage of DNA by mammalian DNA topoisomerase II.
Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., & Chen, G. L. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43815-4 · Cited by 533
Self-citationChen, G. L., Yang, L., Rowe, T. C., Halligan, B. D., Tewey, K. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)90729-5 · Cited by 492
Self-citationA homogeneous type II DNA topoisomerase from HeLa cell nuclei.
Miller, K. G., Liu, L. F., & Englund, P. T. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52552-2 · Cited by 356
Self-citationDouble strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster.
Sander, M., & Hsieh, T. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82081-x · Cited by 285
Cited by
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Self-citationGewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Self-citationTargeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Doxorubicin pathways: pharmacodynamics and adverse effects
Thorn, C. F., Oshiro, C., Marsh, S., Hernandez-Boussard, T., McLeod, H., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833ffb56 · Cited by 1,648
DNA and its associated processes as targets for cancer therapy
Hurley, L. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc749 · Cited by 1,349
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
Anthracycline Chemotherapy and Cardiotoxicity
McGowan, J. V., Chung, R., Maulik, A., Piotrowska, I., Walker, J. M., & Yellon, D. M. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6711-0 · Cited by 956
Etoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 949
Nelson, W. G., & Kastan, M. B. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.3.1815 · Cited by 857
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Mechanistic Pathways of Sex Differences in Cardiovascular Disease
Regitz-Zagrosek, V., & Kararigas, G. (2017) · Physiological Reviews · doi:10.1152/physrev.00021.2015 · Cited by 732
Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia
Škrtić, M., Sriskanthadevan, S., Jhas, B., Gebbia, M., Wang, X., Wang, Z., Hurren, R., Jitkova, Y., Gronda, M., Maclean, N., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.015 · Cited by 678
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Self-citationLipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Liposomal Drug Delivery Systems and Anticancer Drugs
Olusanya, T., Haj Ahmad, R., Ibegbu, D., Smith, J., & Elkordy, A. (2018) · Molecules · doi:10.3390/molecules23040907 · Cited by 603
Andrew MacKay, J., Chen, M., McDaniel, J. R., Liu, W., Simnick, A. J., & Chilkoti, A. (2009) · Nature Materials · doi:10.1038/nmat2569 · Cited by 580
Oxidative stress injury in doxorubicin-induced cardiotoxicity
Songbo, M., Lang, H., Xinyong, C., Bin, X., Ping, Z., & Liang, S. (2019) · Toxicology Letters · doi:10.1016/j.toxlet.2019.02.013 · Cited by 566
Hertzberg, R. P., Caranfa, M. J., & Hecht, S. M. (1989) · Biochemistry · doi:10.1021/bi00437a018 · Cited by 551
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention
Henriksen, P. A. (2018) · Heart · doi:10.1136/heartjnl-2017-312103 · Cited by 536
Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicity
Keizer, H. G., Pinedo, H. M., Schuurhuis, G. J., & Joenje, H. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90088-j · Cited by 517
A comprehensive review on time-tested anticancer drug doxorubicin
Sritharan, S., & Sivalingam, N. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119527 · Cited by 487
Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide
Mizutani, H., Tada-Oikawa, S., Hiraku, Y., Kojima, M., & Kawanishi, S. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.05.040 · Cited by 472
Light‐Activated Hypoxia‐Responsive Nanocarriers for Enhanced Anticancer Therapy
Qian, C., Yu, J., Chen, Y., Hu, Q., Xiao, X., Sun, W., Wang, C., Feng, P., Shen, Q., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201505869 · Cited by 466
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Topoisomerase-targeting antitumor drugs
D'Arpa, P., & Liu, L. F. (1989) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(89)90041-3 · Cited by 434
Self-citationFree radical formation by antitumor quinones
Powis, G. (1989) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(89)90162-7 · Cited by 423
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021) · The FEBS Journal · doi:10.1111/febs.15583 · Cited by 410
How do chemotherapeutic agents damage the ovary?
Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H., & Spears, N. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms022 · Cited by 409
Wang, A. H. J., Ughetto, G., Quigley, G. J., & Rich, A. (1987) · Biochemistry · doi:10.1021/bi00378a025 · Cited by 405
Levine, C., Hiasa, H., & Marians, K. J. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00126-2 · Cited by 391
Topoisomerase IV is a target of quinolones in Escherichia coli.
Khodursky, A. B., Zechiedrich, E. L., & Cozzarelli, N. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11801 · Cited by 378
Fischer, M., Grossmann, P., Padi, M., & DeCaprio, J. A. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw523 · Cited by 330
Antioxidant nutrients and adriamycin toxicity
Quiles, J. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00383-9 · Cited by 362
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Camptothecin and Taxol: Historic Achievements in Natural Products Research
Oberlies, N. H., & Kroll, D. J. (2004) · Journal of Natural Products · doi:10.1021/np030498t · Cited by 353
Hollingshead, L. M., & Faulds, D. (1991) · Drugs · doi:10.2165/00003495-199142040-00010 · Cited by 345
Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115725 · Cited by 334
Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., et al. (2016) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002661 · Cited by 334
Chemotherapy-Induced Weakness and Fatigue in Skeletal Muscle: The Role of Oxidative Stress
Gilliam, L. A. A., & St. Clair, D. K. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3965 · Cited by 324
Recent studies of DNA topoisomerases
Wang, J. C. (1987) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(87)90040-6 · Cited by 320
PIDD Mediates NF-κB Activation in Response to DNA Damage
Janssens, S., Tinel, A., Lippens, S., & Tschopp, J. (2005) · Cell · doi:10.1016/j.cell.2005.09.036 · Cited by 319
Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Doxorubicin-DNA Adducts Induce a Non-Topoisomerase II–Mediated Form of Cell Death
Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R., & Cutts, S. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3410 · Cited by 314
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
SHENKENBERG, T. D., & VON HOFF, D. D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-67 · Cited by 305
Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism
Meredith, A.-M., & Dass, C. R. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12539 · Cited by 303
Liu, J., Luo, Z., Zhang, J., Luo, T., Zhou, J., Zhao, X., & Cai, K. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.008 · Cited by 294
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Azarova, A. M., Lyu, Y. L., Lin, C.-P., Tsai, Y.-C., Lau, J. Y.-N., Wang, J. C., & Liu, L. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704002104 · Cited by 286
Self-citationKunisada, K., Negoro, S., Tone, E., Funamoto, M., Osugi, T., Yamada, S., Okabe, M., Kishimoto, T., & Yamauchi-Takihara, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.315 · Cited by 273
Barnett, K. C., Coronas-Serna, J. M., Zhou, W., Ernandes, M. J., Cao, A., Kranzusch, P. J., & Kagan, J. C. (2019) · Cell · doi:10.1016/j.cell.2019.01.049 · Cited by 271
Metabolism and reactions of quinoid anticancer agents
Powis, G. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90105-7 · Cited by 270
Activation of NF-κB by Antineoplastic Agents
Das, K. C., & White, C. W. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14914 · Cited by 269
DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors.
Chen, A. Y., Yu, C., Gatto, B., & Liu, L. F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8131 · Cited by 268
Self-citationHypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review
Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.041 · Cited by 263
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
Marinello, J., Delcuratolo, M., & Capranico, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113480 · Cited by 258
In Vitro and in Vivo Anticancer Activity of Copper Bis(thiosemicarbazone) Complexes
Palanimuthu, D., Shinde, S. V., Somasundaram, K., & Samuelson, A. G. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm300938r · Cited by 257
Mitoxantrone, More than Just Another Topoisomerase II Poison
Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21364 · Cited by 253
Biochemical basis for the interactions of type I and type II topoisomerases with DNA
Osheroff, N. (1989) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(89)90108-3 · Cited by 252
Negoro, S., Kunisada, K., Fujio, Y., Funamoto, M., Darville, M. I., Eizirik, D. L., Osugi, T., Izumi, M., Oshima, Y., Nakaoka, Y., et al. (2001) · Circulation · doi:10.1161/hc3401.095947 · Cited by 252
Plosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199345050-00011 · Cited by 223
Cardiac spheroids as promising in vitro models to study the human heart microenvironment
Polonchuk, L., Chabria, M., Badi, L., Hoflack, J.-C., Figtree, G., Davies, M. J., & Gentile, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-06385-8 · Cited by 223
S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function
Cliby, W. A., Lewis, K. A., Lilly, K. K., & Kaufmann, S. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106287200 · Cited by 205
Nanotools for Sepsis Diagnosis and Treatment
Papafilippou, L., Claxton, A., Dark, P., Kostarelos, K., & Hadjidemetriou, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001378 · Cited by 118
Mrass, P., Rendl, M., Mildner, M., Gruber, F., Lengauer, B., Ballaun, C., Eckhart, L., & Tschachler, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1129 · Cited by 112
Doxorubicin‐Induced Cardiomyopathy in Children
Mancilla, T. R., Iskra, B., & Aune, G. J. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180017 · Cited by 108
Doxorubicin-induced cardiotoxicity: causative factors and possible interventions
Jones, I. C., & Dass, C. R. (2022) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgac063 · Cited by 91
DNA damage by drugs and radiation: What is important and how is it measured?
Whitaker, S. J. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90432-2 · Cited by 43
Metadata
- Authors
- Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F.
- Venue
- Science
- Published
- 1984-10-26
- Volume
- 226
- Issue
- 4673
- Pages
- 466-468
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2016254453
- Cited by
- 1,538
- References
- 14
- FWCI
- 10.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.